Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Oct 9;5(10):e1450. doi: 10.1038/cddis.2014.396

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0

PMC Copyright notice

BETi enhanced the growth inhibition of rapamycin and reduced the rapamycin-induced activation of AKT in PanNET Cells. (a) Synergistic growth inhibition of CPI203 and rapamycin on BON-1 or QGP-1 cells. BON-1 or QGP-1 cells were treated with CPI203, rapamycin or in combination as indicated. Cell viability was determined at 72 h. Error bars represent S.E.M., n=3. Combination index (CI) was calculated using CompuSyn software. *P<0.01 versus single treatment; ^#P<0.01 versus one single treatment but P=0.01 versus the other single treatment. (b) Synergistic growth inhibition of (+)-JQ1 and rapamycin on BON-1 or QGP-1 cells, which was performed in the same way as that in (a). (c) Immunoblots of MYC, mTOR downstream targets and AKT at 24 and 48 h of BON-1 and QGP-1 cells treated with 50 nM CPI203 (BON-1) or 500 nM (QGP-1), 1 μM rapamycin or in combinations. (d) and (e) Immunoblots of MYC, mTOR downstream targets and AKT at 48 h of BON-1 cells (d) or of QGP-1 cells (e) treated with a range of doses of CPI203 or rapamycin as indicated

BETi enhanced the growth inhibition of rapamycin and reduced the rapamycin-induced activation of AKT in PanNET Cells. (a) Synergistic growth inhibition of CPI203 and rapamycin on BON-1 or QGP-1 cells. BON-1 or QGP-1 cells were treated with CPI203, rapamycin or in combination as indicated. Cell viability was determined at 72 h. Error bars represent S.E.M., n=3. Combination index (CI) was calculated using CompuSyn software. *P<0.01 versus single treatment; ^#P<0.01 versus one single treatment but P=0.01 versus the other single treatment. (b) Synergistic growth inhibition of (+)-JQ1 and rapamycin on BON-1 or QGP-1 cells, which was performed in the same way as that in (a). (c) Immunoblots of MYC, mTOR downstream targets and AKT at 24 and 48 h of BON-1 and QGP-1 cells treated with 50 nM CPI203 (BON-1) or 500 nM (QGP-1), 1 μM rapamycin or in combinations. (d) and (e) Immunoblots of MYC, mTOR downstream targets and AKT at 48 h of BON-1 cells (d) or of QGP-1 cells (e) treated with a range of doses of CPI203 or rapamycin as indicated